ProShares UltraShort NASDAQ Biotechnology
11 hedge funds and large institutions have $4.82M invested in ProShares UltraShort NASDAQ Biotechnology in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
1.91% more ownership
Funds ownership: 1.06% → 2.97% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less call options, than puts
Call options by funds: $599K | Put options by funds: $772K
Holders
11
Holding in Top 10
1
Calls
$599K
Puts
$772K
Top Buyers
| 1 | +$982K | |
| 2 | +$952K | |
| 3 | +$695K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$188K |
| 5 |
Citigroup
New York
|
+$45K |
Top Sellers
| 1 | -$60.7K | |
| 2 | -$19.9K | |
| 3 | -$10K | |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$2K |